Affiliation:
1. Moscow Regional Research Institute for Obstetrics and Gynecology
Abstract
Data on risks of development of oncological diseases of bodies of reproductive system in women during menopausal transition and in a postmenopause are submitted at treatment of menopausal frustration by the preparations intended for menopausal hormonal therapy, the containing various doses of estrogen and progestogen used in the cyclic or continuous mode.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference46 articles.
1. Furness S., Roberts H., Marjoribanks J., Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst. Rev. Art. 2012; 8DOI: dx.doi.org/10,1002/14651858. CD 000402.pub4.
2. Roberts, H., Hickey, M., Lethaby, A.A. Cochrane review summary. Maturitas. 2014; 77:4-6.
3. Soules, M.R., Sherman, S., Parrott, E. Executive summary: Stages of Reproductive Ageing Workshop (STRAW). FertilSteril. 2001; 76: 874-878.
4. Writing. Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc. 1996; 275: 370-375.
5. Politi M.C., Schleinitz M. D., Col, N.F. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Inter Med. 2008; 23: 1507-1513.